Guggenheim Has Lowered Expectations for Nanobiotix (NASDAQ:NBTX) Stock Price

Nanobiotix (NASDAQ:NBTX) had its target price trimmed by Guggenheim from $12.00 to $8.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, UBS Group upgraded shares of Nanobiotix to a “hold” rating in a research note on Monday, February 17th.

Nanobiotix Stock Performance

Shares of Nanobiotix stock opened at $3.27 on Friday. Nanobiotix has a 52-week low of $2.76 and a 52-week high of $7.51. The stock’s 50-day simple moving average is $3.59 and its 200 day simple moving average is $3.80.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC bought a new position in shares of Nanobiotix in the fourth quarter valued at approximately $39,000. Jane Street Group LLC purchased a new stake in Nanobiotix in the 4th quarter worth approximately $73,000. Geode Capital Management LLC bought a new position in Nanobiotix in the 4th quarter valued at $29,000. Finally, OLD Mission Capital LLC purchased a new position in shares of Nanobiotix during the 4th quarter valued at $139,000. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.